SPYRE THERAPEUTICS INC (SYRE) Stock Price & Overview
NASDAQ:SYRE • US00773J2024
Current stock price
The current stock price of SYRE is 51.77 USD. Today SYRE is down by -0.4%. In the past month the price increased by 24.75%. In the past year, price increased by 323.65%.
SYRE Key Statistics
- Market Cap
- 4.066B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.22
- Dividend Yield
- N/A
SYRE Stock Performance
SYRE Stock Chart
SYRE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SYRE. When comparing the yearly performance of all stocks, SYRE is one of the better performing stocks in the market, outperforming 98.48% of all stocks.
SYRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SYRE. While SYRE has a great health rating, there are worries on its profitability.
SYRE Earnings
SYRE Forecast & Estimates
21 analysts have analysed SYRE and the average price target is 62 USD. This implies a price increase of 19.76% is expected in the next year compared to the current price of 51.77.
SYRE Groups
Sector & Classification
SYRE Financial Highlights
Over the last trailing twelve months SYRE reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS increased by 47.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.49% | ||
| ROE | -32.69% | ||
| Debt/Equity | 0 |
SYRE Ownership
SYRE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.31 | 375.559B | ||
| AMGN | AMGEN INC | 15.58 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 16.07 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.42 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.06 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 11.02 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.24 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.66 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SYRE
Company Profile
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Company Info
IPO: 2016-04-07
SPYRE THERAPEUTICS INC
221 Crescent Street, Suite 105
Waltham MASSACHUSETTS US
Employees: 102
Phone: 16176515940.0
SPYRE THERAPEUTICS INC / SYRE FAQ
What does SPYRE THERAPEUTICS INC do?
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
What is the stock price of SPYRE THERAPEUTICS INC today?
The current stock price of SYRE is 51.77 USD. The price decreased by -0.4% in the last trading session.
Does SYRE stock pay dividends?
SYRE does not pay a dividend.
How is the ChartMill rating for SPYRE THERAPEUTICS INC?
SYRE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in SPYRE THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SYRE.
What is the outstanding short interest for SPYRE THERAPEUTICS INC?
The outstanding short interest for SPYRE THERAPEUTICS INC (SYRE) is 14.26% of its float.